Losartan Potassium Tablet, Film Coated
Product Images NDC 43063-954

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 43063-954). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

43063954 Label (43063954)

43063954 Label (43063954)
This is a medicine called Losartan Potassium USP 100 mg with 30 tablets per bottle. It is suggested to discontinue the use of the medicine once pregnancy is detected. The medicine bottle has LOT number D19E38, and its expiry date is 04/2021. It also has some FDA warnings and dosage recommendations. There are some illegible texts in the description.*
FDA Label Image

Figure1 (Losartan Fig1)

Figure1 (Losartan Fig1)
FDA Label Image

Figure2 (Losartan Fig2)

Figure2 (Losartan Fig2)
FDA Label Image

Figure 3 (Losartan Fig3)

Figure 3 (Losartan Fig3)
This appears to be a table or chart displaying information about primary endpoint events within demographic subgroups for a study or experiment. The table includes data for different age groups, gender, and race as well as the overall results. There is also information about other factors such as history of VD and levels of potassium and fever. However, as there are a lot of errors in the text due to , it is difficult to interpret the data accurately.*
FDA Label Image

Figure-4 (Losartan Fig4)

Figure-4 (Losartan Fig4)
This appears to be a table displaying the percentage of patients with events related to Losttan Potassium versus Placebo. It suggests that 60% of patients taking Losttan Potassium had an event, while 40% of patients who took Placebo had a similar event. There is information on risk reduction and p-value included, suggesting perhaps there was a statistical analysis performed. However, without more information, it's difficult to fully understand the context or implications.*
FDA Label Image

Chemical Structure (Losartan Str)

Chemical Structure (Losartan Str)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.